HSBC Holdings
NMRA icon

HSBC Holdings’s Neumora Therapeutics NMRA Stock Holding History

HSBC Holdings’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.7K Sell
11,387
-3,573
-24% -$9.26K ﹤0.01% 2856
2025
Q4 		$26.9K Buy
+14,960
New +$32.8K ﹤0.01% 2892
2024
Q4 		– Sell
-10,067
Closed -$133K – 3194
2024
Q3 		$133K Buy
+10,067
New +$117K ﹤0.01% 2739

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

HSBC Holdings's NMRA Position: Q1 2026 in Review

HSBC Holdings reduced its Neumora Therapeutics (NMRA) stake by 24% in Q1 2026, selling an estimated $9.26K and leaving 11,387 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2856.

HSBC Holdings first reported a position in NMRA in Q3 2024 and has held it in 3 quarters since. The position peaked at $133K in Q3 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • HSBC Holdings held 11,387 shares of Neumora Therapeutics worth $22.7K as of Q1 2026.
  • HSBC Holdings sold 3,573 Neumora Therapeutics shares in Q1 2026, an estimated $9.26K.
  • Neumora Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2856 holding.
  • HSBC Holdings first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • HSBC Holdings's Neumora Therapeutics position peaked at $133K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.